Skip to main content
Therapy by omission: observation as a strategy in JMML.
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.
Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia.
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.
Venous Thromboembolism in Individuals with Sickle Cell Disease- a Retrospective Review of This Understudied Problem
Primary Care Screening for Von Willebrand Disease in African American Adolescents with Heavy Menstrual Bleeding
Motivations and Experiences of Physicians Who Pursued Hemostasis and Thrombosis Fellowship - a Survey Study
Development and Validation of a Risk Assessment Model for Venous Thromboembolism in the Pediatric Intensive Care Unit
Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States.
Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent ß-Thalassemia.